Specialised Therapeutics’ breast cancer drug gets Philippines FDA approval
Pharmaceutical Technology
JULY 8, 2022
The company claimed that the utmost benefit is reported in hormone-receptor positive (HR+) women and those who commence treatment with Nerlynx within a year of receiving trastuzumab-based therapy. Nerlynx is the first drug in Specialised Therapeutics’ therapeutic portfolio to obtain approval in the region.
Let's personalize your content